Remestemcel-L
Acute Respiratory Distress Syndrome (ARDS)
Phase 2/3Ongoing
Key Facts
About Mesoblast
Mesoblast is a global leader in developing allogeneic (off-the-shelf) cellular medicines derived from its proprietary mesenchymal lineage cell technology platform. Its most advanced candidate, remestemcel-L, has a Biologics License Application (BLA) under priority review with the FDA for pediatric SR-aGVHD, with a PDUFA date of August 2, 2024. The company's strategic focus is on advancing its late-stage pipeline in inflammatory conditions with high unmet need while leveraging its scalable manufacturing platform.
View full company profile